Alpha Tau Medical Ltd. current report, Q4 FY2023

Alpha Tau Medical Ltd. Form 6-K Summary

Business Context and Reporting Period

Alpha Tau Medical Ltd., an Israel-based foreign private issuer, furnished a Form 6-K for October 2023, dated October 24, 2023. The filing reports that the company issued a press release announcing the appointment of former U.S. Food and Drug Administration Commissioner Stephen M. Hahn, M.D., to its advisory board.

Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating performance, or other financial metrics.

Material Changes Versus Prior Period

No financial or operating changes versus a prior comparable period are disclosed. The reported corporate development is the addition of Dr. Hahn to the company’s advisory board.

Guidance, Outlook, Risks, and Unusual Items

The provided filing text does not include management guidance, financial outlook, risk updates, contingencies, or unusual financial items. The press release is identified as Exhibit 99.1, but its substantive text is not included in the source provided.

Important Facts to Verify

  • Review Exhibit 99.1 for the full details of Dr. Hahn’s appointment, responsibilities, and any related compensation or strategic commentary.
  • Confirm whether the appointment affects the company’s regulatory, clinical, or commercialization strategy.
  • Refer to the company’s latest Form 20-F and subsequent filings for current financial condition, liquidity, clinical progress, and risk factors.
  • Note that the information was furnished rather than filed for purposes of Section 18 of the Exchange Act, except as otherwise expressly provided.